Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Shaw Leaves Lilly To Helm Gilead’s Kite

Jul 11 2019

• By Joseph Haas

Christi Shaw — Christi Shaw led Lilly Bio-Medicines since January 2017

Related Content

Taltz Results In Spondyloarthritis Add To Lilly Franchise Hopes

Apr 23 2019

Lilly Says Volume Growth Strategy, Launches Working Despite Price Pressures

Apr 30 2019

Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results

Apr 19 2019

Lilly Management Reorg Brings In Shaw To Oversee Bio-Medicines

Jan 05 2017

Lilly's New Year Resolution: Make New Launches Into Blockbusters

Dec 20 2018

A Q&A With Lilly Biomedicines President Christi Shaw

May 25 2018

Gilead To Let Kite Fly Free; O’Day Says It Will Become Separate Business Unit

May 02 2019

Related Companies

Eli Lilly and Company

Gilead Sciences, Inc.

Kite Pharma, Inc.

Johnson & Johnson

Johnson & Johnson

Novartis AG

Amgen, Inc.

Pfizer Inc.

Additional Topics

Business Strategies Leadership Commercial Gene Therapy ImmunoOncology Companies BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window